Lotte Biologics’ new leadership struggles to brush off doubts
Lotte Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) established in 2022, is struggling to dispel concerns about its viability, as its newly nominated CEO, who was appointed in an attempt to address the company's challenges, is generating more skepticism than optimism.
Dec 12, 2024By Nam Hyun-woo